SS Innovations Touts 15,000 Robotic Surgeries, Telesurgery Milestone as Growth Strategy Accelerates

SS Innovations International reports over 15,000 SSi Mantra procedures and 200 telesurgeries while outlining expansion plans in manufacturing and international regulatory markets, signaling growing commercial traction in robotic surgery.

Chicago Metrowire Staff
••Healthcare
SS Innovations Touts 15,000 Robotic Surgeries, Telesurgery Milestone as Growth Strategy Accelerates

SS Innovations International (NASDAQ: SSII) is positioning its SSi Mantra robotic surgical platform for broader adoption after disclosing that more than 15,000 procedures have been performed using its systems, including approximately 750 cardiac surgeries. The disclosure, made by CEO Dr. Sudhir Srivastava in an interview with The Motley Fool, matters because it moves the company beyond the development stage into a phase where clinical volume, commercial revenue and international expansion plans are beginning to reinforce one another.

The company said more than 200 telesurgeries have been performed using the SSi Mantra platform, including 27 cardiac procedures. Telesurgery, in which a specialist guides a robotic operation remotely, is significant because it could extend specialist surgical expertise to underserved communities that lack on-site access to advanced care. For SS Innovations, the telesurgery tally is also a differentiator that supports its argument that the platform is not merely a lower-cost alternative but a system capable of supporting advanced clinical use cases.

Srivastava highlighted the SSi Mantra's differentiated engineering, including 4K 3D visualization, surgeon-controlled anatomical imaging and a modular design that supports up to five robotic arms. That modularity may matter commercially because it allows hospitals to configure systems around their needs rather than committing to a fixed architecture, potentially lowering adoption barriers. The company's growth strategy was detailed further in a recent interview summary available through https://ibn.fm/EJk05, which outlines management's views on technology, clinical experience and affordability.

Manufacturing is another pillar of the strategy. SS Innovations is preparing to expand its Indian production capacity through a planned 10-acre facility, with the objective of bringing additional production capabilities in-house. Bringing more manufacturing under its own control could help the company manage costs and supply as order volumes rise, an important consideration given that affordability is central to its pitch to hospitals in emerging markets.

Regulatory progress in Europe and the United States is also advancing, with management targeting international expansion through direct sales and opportunities in ambulatory surgery centers. Those markets are significant because they represent large, higher-reimbursement healthcare systems where approval would substantially widen the addressable customer base. The company is experiencing strong commercial momentum, with first-half 2026 revenue increasing approximately 66% year-over-year to about $25 million.

For investors, the combination of clinical volume, telesurgery experience, manufacturing expansion and regulatory filings provides a more complete picture of how SS Innovations intends to compete in the surgical robotics market. The company's latest news and updates are available through https://ibn.fm/SSII, and the original release can be viewed at www.newmediawire.com. Additional details on the company are available via SS Innovations International (NASDAQ: SSII).

Blockchain Registration

QR Code for Blockchain Registration